Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks

Core Insights - Inspira Technologies announced a strategic commercial showcase of its FDA-cleared INSPIRA™ ART100 system at the AmSECT 64th International Conference, scheduled for March 25–29, 2026, in Austin, Texas [1][4] Group 1: Commercial Strategy - The showcase aims to engage directly with decision-makers in hospitals, enhancing the company's U.S. commercial strategy and expanding clinical partnerships and distribution [3][7] - The ART100 system has received FDA 510(k) clearance, validating its readiness for clinical integration in cardiopulmonary bypass procedures [7] Group 2: Product Overview - The INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., serving as a foundation for the development of the next-generation INSPIRA ART500 system [5] - The company is also advancing the HYLA™ blood sensor platform, which offers continuous, non-invasive monitoring [5] Group 3: Industry Context - The AmSECT International Conference is a key global event for perfusion technology, featuring cutting-edge medical technologies and expert-led sessions [4]